Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Teijin Licenses Drug for Osteoporosis from Dong Wha Pharm. of South Korea
April 14, 2008
- DSP, Ajinomoto Apply for Combination of Gasmotin and Niflec
April 14, 2008
- TOPICS／7,733 Pass National Exam for Medical Practitioners
April 14, 2008
- STATISTICS／Domestic Drug Production Up 0.7% to \6,438.1 Bil. in 2006
April 14, 2008
- Novel Oral Anticoagulant Pradaxa Approved in EU: Boehringer Ingelheim
April 14, 2008
- Awareness of Peripheral Arterial Disease Low: J&J Survey
April 14, 2008
- Takeda Licenses Prostate Cancer Vaccine from Cell Genesys
April 14, 2008
- Alimta Receives Positive CHMP Opinion for NSCLC First-Line Treatment: Eli Lilly
April 14, 2008
- Antidepressants Often Used Off-Label to Treat Chronic Pain
April 14, 2008
- Takeda Ties Up with JPRI for Sabin-Inactivated Poliovirus Vaccine
April 14, 2008
- REGULATORY NEWS IN BRIEF
April 14, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 14, 2008
- Asahi Kasei to License New Products to Strengthen Its R&D Pipeline
April 14, 2008
- TOPICS／Olopatadine Receives 2008 PSJ Award for Drug R&D 2008
April 14, 2008
- DSP to Choose 2nd Global Strategic Product by Fall
April 14, 2008
- Isao Teshirogi Appointed Shionogi President
April 7, 2008
- PMDA to Enhance Cooperation with Authorities in Other East Asian Countries: Mr Mori
April 7, 2008
- SELF-MEDICATION NEWS IN BRIEF
April 7, 2008
- Notices Received for 35 Collaborative Multinational Trials: Mr Mori
April 7, 2008
- Serious Effort Needed to Bring about Improvements : FJPWA President Matsutani
April 7, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…